The Clinical Research Division is under the leadership of Dr Vinodh Edward, Managing Director: Clinical Research Division.
About Clinical Research
Focus in 2015 shifted from the exclusive implementation of sponsored/sub-contracted research to both the continued implementation of sponsored/contracted research and submitting / securing Aurum led Investigator-initiated clinical research (n=6), all believed to contribute significantly to future Aurum intellectual property.
Dr Vinodh Edward - Managing Director: Clinical Research Division
Dr Edward has been a basic sciences researcher since 2000. He has been involved in clinical trials management since 2005. Dr Edward is registered as a professional natural scientist, which allows him to have a broad focus in the biological sciences.
Clinical Research Sites
There are four Clinical Research Sites which include Tembisa, Rustenburg, Klerksdorp and Welkom. These four sites are home to a large number of HIV and TB researchers.
Tembisa Clinical Research Site
Rustenburg Clinical Research Site
Klerksdorp Clinical Research Site
Welkom Clinical Research Site
Appointments made into key positions include:
- Tanya Nielson – Head of Department (Clinical Research division)
- Trevor Beattie – Programme Manager (TB Vaccines, Clinical Research division)
- Tania Adonis – Programme Manager (HIV Vaccines, Clinical Research division)
- Dr Pholo Maenetje – Programme Manager (Basic Sciences and Special Projects)
- Lungile Mbata – Programme Manager (TB Treatment, Clinical Research division)
- Heeran Makkan – Programme Manager (HIV Treatment and Prevention, Clinical Research division)
- Dr Craig Innes – CRS Leader at the Gavin J Churchyard Legacy Centre / Klerksdorp CRC
- Dr William Brumskine – CRS Leader at the Rustenburg CRC
- Dr Modulakgotla Sebe – CRS Leader at the Tembisa CRC
- Dr Mandla Mlotshwa - Scientist based at the Tembisa CRC
- Stacey Lawrence – MRC ACT4TB/HIV Consortium Project Coordinator (Clinical Research division)
All studies fall into one of five programmatic areas:
The availability of a new effective TB vaccine would be the single greatest advance towards eradicating TB both nationally and globally.
In 2015 alone, a total of five TB vaccine clinical research were conducted at the Gavin J Churchyard legacy Centre / Klerksdorp CRC and Tembisa CRC. Enrolment into the AERAS GSK TB 018 TB vaccine (sharing significant adjuvant homology with the recently developed RTS, S GSK malaria vaccine) study was completed at the Klerksdorp and Tembisa CRCs, where 328 participants were enrolled over a period of a year and 52 participants over a record breaking three months period, respectively.
Together with partner sites and TB Vaccine world experts, two competing TB vaccine clinical research proposals were submitted for review to the European Developing Countries Trials Partnership for potential funding.